We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Nutra Gp | LSE:ONG | London | Ordinary Share | GB00B3LXPB43 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 4.00 | GBX |
Oxford Nutrascience (ONG) Share Charts1 Year Oxford Nutrascience Chart |
|
1 Month Oxford Nutrascience Chart |
Intraday Oxford Nutrascience Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/5/2011 | 18:22 | Oxford Nutrascience Group - 2011 | 127 |
| 10/2/2011 | 14:05 | Ong Beng Seng, Singapore-based Financier | 19 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 19/4/2011 06:34 by wilba ONG signed 7 year licensing deal in Brazil. The good news just keeps coming. |
Posted at 05/4/2011 08:13 by wilba Two trades dissapeared from ONG this am prior to 09:00. A 350k approx sell and a 250k buy. Then the 1 mill buy and two mill buys appeared and the bid dropped to 3.25. There has been some share changes here over the last month between II's and company holders. Something going on here prior to results. Expected near term. |
Posted at 11/2/2011 19:13 by mike111d Wilba, thanks but no thanks. I would rather invest in something with some substance to it, than a pure ramp on the boards. Currently invested at placing prices in a few places, where I anticipate decent near term returns and little hassle whilst holding. So no sorry I am not going to buy ONG to give someone else the chance they are hoping for to get their stake money back out. |
Posted at 11/2/2011 09:21 by excellance 7b,i know what you mean about ONG, but you have to take a longer view, and at the current mkt cap the share price is good value... meanwhile SAR are also a long term share but their share price was silly high, and the placing at 1.5p proved that... SAR have been given a dose of reality, but dont get me wrong i think they will be valued at a multiple of their current sp, but to think it would happen over night is a little short sighted... ONG are good value at up to £10m mkt cap IMHO |
Posted at 11/2/2011 09:07 by excellance looks good to me, cash in the bank, no debt, patents in many countries, licensed by oxford uni, retailing in boots... high profile names associated with this newly listed company...i tried to buy on tdw this am for my sipp but would you believe they did not recognise this share as eligible for a sipp... so a phone call later they agreed to admit it to their list but the share price had risen 20%... damn TDW SIPP svs is poor... |
Posted at 11/2/2011 08:11 by wilba Lol. Div the market cap by shares in issue = guestimate share price based on cash in bank.You then add theoretical intangibles values. GLA. Looking great. |
Posted at 11/2/2011 07:19 by oakville ONG"MARY Poppins once sang that a spoonful of sugar helps the medicine go down. Now an Oxfordshire biotech firm has set out to prove her right by developing a new form of a common painkiller that tastes a lot sweeter. Researchers at Oxford Nutrascience have been working on ways of making ibuprofen more palatable by cutting out the burning sensation it sends to the throat and replacing it with more pleasant flavours. Now the company, which span out of the chemistry department of Oxford University in 2008, has signed a licensing agreement with Isis Innovation, the university's technology transfer company, to develop and commercialise the technology. As a result, the first ibuprofen "chews" and liquid could be on the market as early as next year. Marcelo Bravo, executive chairman and chief technology officer at Oxford Nutrascience, said: "Ibuprofen has been around a long time but delivers a burning sensation to the throat. "Using this technology we can deliver chewable and liquid forms of the drug using much higher doses suitable for some treatment needs and now we are working out how to take this to an industrial level." The potential of the breakthrough is huge. Mr Bravo said the current market for ibuprofen, originally invented by chemists at Boots, was £1.5bn a year. He added that manufacturers of ibuprofen had been "very enthusiastic" about the development which could lead to different flavours being used in different markets depending on local tastes. "The response has been outstanding. We are talking to the top five people in the world right now - it is a question of execution. "The regulatory experts are still quite complex but we are aiming to have a licence for early products some time in 2012." Oxford Nutrascience based at the Begbroke Innovation Centre, Yarnton, has a staff of four but uses a wide range of research partners to develop its technology. As well as ibuprofen, the company is developing new its taste-masking technology for a range of products, including fish oil and calcium supplements." |
Posted at 10/2/2011 17:46 by 22hoper Wilba, when you consider that most companies at this share price have around 2 billion shares in public issue. Then compare ong with their fantastic product and a tiny amount of shares in public issue. Then just a incy bit of volume and it will zoooooom. |
Posted at 10/2/2011 17:34 by wilba Scratch what i said. Further down the web page is this.Price Data Currency UK Pounds Price 2.88p Change Today +0.75p Volume 2,056,028 10-Feb-11 Close 2.88p Shares Issued 464.02m Market Cap £13.36m Shares not in Public hands In the terms of the AIM Rules published February 2010 and insofar as it is aware, at 28 July 2010, 75.65% of the Company's AIM securities were not held in public hands. That cals at 116m shares in public circulation. |
Posted at 10/2/2011 17:26 by wilba Major ShareholdersAs at 28 July 2010, shareholders holding more than 3% of the share capital of Oxford Nutrascience Group plc were Name of shareholder Percentage of total voting rights held Ora (Guernsey) Limited 34.89% David Norwood 18.86% Marcelo Bravo 13.47% Robert Quested 9.19% David Richardson 5.53% Richard Griffiths 3.08% Less than 20% of these shares are floating in public hands. Am i reading this wrong or is this a bloody goldmine. Products, licenses, limited share availability and cash. I think im in heaven.............. Well lets get some buying and this will fly. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
